|
Application
|
Description
|
Meeting Date
|
Committee Response
|
|
RP1421
HiPhorius™
(6-phytase (EC 3.1.3.26) solid (10 and 40) and liquid (20L and 50L) forms)
|
|
Apr 2024
Jul 2024
Sep 2024
Oct 2024
|
|
|
RP1280
Formaldehyde
GB pre-validation request for additional use for turkeys for fattening.
(This application was withdrawn September 2024)
|
|
Apr 2024
Jul 2024
|
-
The additive was assessed previously in December 2023 and the Committee concluded that efficacy was demonstrated under the proposed conditions of use.
-
Due to gaps in technical documentation, additional information was requested from the applicant.
-
In April 2024, Members decided to postpone discussion of this application until further information has been provided by the applicant relating to the identity of the additive.
|
|
RP1579
Pediococcus acidilactici CNCM I-4622
(This application was withdrawn Aug 2024)
|
|
Apr 2024
Jun 2024
Jul 2024
|
|
|
RP1335
Bio D® 1.25% 25-hydroxycholecalciferol
|
|
Apr 2024
Jun 2024
Aug 2024
|
-
An additive with the same active ingredient is already authorised for use in poultry, pigs and all ruminants, however this additive is produced by the non-QPS organism, Pseudonocardia autotrophica.
-
In April 2024, after reviewing the information provided, the Committee decided that the application could not be considered for full risk assessment by ACAF at this stage.
-
This assessment was approved by Decision Panel on 25 June 2024. Assessment route: ABB.
-
The FSA/FSS published a Safety Assessment in August 2024.
-
The FSA/FSS concluded the additive and production strain were correctly identified. It is not a dusty product; however, the particle size distribution was not characterised fully. The additive is stable for 24 months at room temperature and acceptably stable in premixtures and feed. Stability during pelleting could not be determined. Homogeneity in feed was demonstrated. The presence of live cells from the production organism in the final form of the product could not be ruled out.
-
The FSA/FSS cannot conclude on the safety of the additive Bio D® 1.25% for the target species and consumers as currently formulated when produced by P. autotrophica M301 (DSM 32858).
-
The additive is not a skin irritant or sensitiser and is not an eye irritant. The additive has a low dusting potential which would limit exposure through inhalation; however, uncertainties remain on its particle size distribution. Conclusions could not be drawn on the systemic toxicity potential of the additive, and the presence of live cells from the production strain in the final product could not be ruled out. These factors pose a concern for the safety for the user/worker.
-
The additive can be considered safe for the environment.
-
25-hydroxycholecalciferol can be considered efficacious for the target species at the proposed doses of inclusion. Conclusions on chickens for fattening can be extrapolated to ornamental birds.
|
|
RP1072
Avatec® 150G
Lasalocid A sodium
|
-
Chickens for fattening; Chickens reared for laying. Turkeys for fattening; Minor avian species (pheasants, guinea fowl, quails and partridges), except laying birds
|
Apr 2024
Sep 2024
Oct 2024
Dec 2024
|
-
The Committee concluded that the additive is an eye irritant, but is not a skin irritant or skin sensitiser, the additive should be regarded as harmful by inhalation and appropriate PPE should be used when handling.
|
|
RP1137
CanBiocin K-9 Heritage Probiotic Blend ®
(This application was withdrawn May 2024)
|
|
Apr 2024
|
|
|
RP1243
L-methionine (C. glutamicum & E.coli)
|
|
Apr 2024
Jul 2024
Oct 2024
Dec 2024
|
-
In April 2024, due to gaps in technical documentation, additional information was requested from the applicant.
-
Further information was requested from the applicant in July 2024 as the Committee could not conclude on the additive.
-
In October 2024 the Committee was presented with the draft of the Committee’s Advice documents.
|
|
RP1282
Levilactobacillus brevis DSMZ 21982
|
|
Apr 2024
|
|
|
RP1298
Ronozyme® HiPhos
|
|
Apr 2024
Jun 2024
Sep 2024
Oct 2024
Dec 2024
|
-
In June 2024 Members reviewed the information provided by the applicant, it was deemed insufficient, and further information was requested to ensure laboratories used are compliant with internationally recognised standards.
-
The FSA/FSS concluded, based on the ACAF’s advice, that the additive was correctly characterised, and that it is stable for 24 months with loss of activity compensated for through additive overfill. No further concerns were raised for the identity section of the additive.
-
The proposed level of inclusion of the additive in feed is safe for the target species, the consumer and the environment. The active substance is non-irritant to the skin and eyes; however, it is regarded as a potential respiratory sensitiser and, in the absence of skin sensitisation tests, a potential skin sensitiser.
-
Ronozyme® HiPhos is efficacious in poultry, weaned piglets, pigs for fattening and sows at the proposed dose range of 500 – 4,000 FYT/kg of feed.
|
|
RP1341
Avizyme® 1505
Containing endo-1,4-beta-xylanase produced by Trichoderma reesei (ATCC PTA 5588), subtilisin protease produced by Bacillus subtilis (ATCC 2107) and alpha-amylase produced by Bacillus amyloliquefaciens (ATCC 3978)
|
|
Apr 2024
Jul 2024
Sep 2024
Oct 2024
Dec 2024
|
-
In the April 2024 meeting, The Committee reviewed the updated bioinformatics data. Members were unable to conclude on the presence of AMR genes in the final product. MSDS documents were also unsuitable for assessment and no skin sensitisation studies were provided; further information was requested from the applicant.
-
The FSA/FSS concluded, based on the ACAF’s advice, that the additive was correctly characterised, and that the additive is stable in premixtures and feedingstuffs for 16 months at 20°C. The additive is stable during pelleting at 90°C for 30 seconds. Homogeneity in feed was also demonstrated.
-
The additive can be considered safe for the target animal, the consumer and the environment. The additive is a mild irritant to the skin and eyes and is not a dermal sensitiser. The additive contains enzymes that are potential respiratory sensitisers, and measures should be taken to avoid contact through inhalation.
-
It was concluded that Avizyme® 1505 is efficacious for all avian species for fattening, reared for breeding and reared for laying (except ducks), and for all avian species for laying (except ducks) at the proposed inclusion rates detailed under the conditions of use of the additive. Efficacy in ducks at the proposed inclusion rate was only demonstrated for the first 42 days.
|
|
RP1512
PB6
Bacillus velezensis ATCC PTA-6737
|
|
Apr 2024
Jun 2024
Sep 2024
Oct 2024
Dec 2024
Feb 2025
|
-
In April 2024, the Committee concluded that the additive is efficacious in weaned piglets and has the potential to be efficacious in sows and growing pigs. They also concluded that since the additive is regarded as a respiratory sensitiser at any level of inhalation exposure, and as the dusting potential values given are quite high, measures will be needed to minimise worker exposure by inhalation. More information was requested from the applicant to support other sections of the dossier.
-
In June 2024, the Committee reviewed the information provided by the applicant, it was deemed unsatisfactory and further information was requested regarding testing methods, compliance with international standards and MSDS documentation.
-
The FSA/FSS concluded, based on the ACAF’s advice, that the additive was correctly identified and characterised, and that it is stable for 18 months at room temperature, for 6 months as part of a mineral premix and a finished mash feed, and for 3 months after pelleting when held at a maximum of 90°C for 45 seconds. Homogeneity was also demonstrated.
-
The ACAF concluded that the additive is efficacious in weaned piglets at a dose of 1 x 107 CFU/kg complete feed. The Committee also concluded that the additive has the potential to be efficacious in sows and minor reproductive species at a dose of 1 x 108 CFU/kg complete feed. The Committee could not accept the applicant’s specific request for extrapolation from piglets to all growing pigs due to lack of evidence for efficacy when fed at the lower dose (1 x 107 CFU/kg) proposed in pigs. However, given the presence of three significant piglet trials and three significant sow trials the Committee was satisfied that the studies provided supported efficacy in all pigs when the higher dose of 1 x 108 CFU/kg was utilised for pigs in the fattening phase.
|
|
RP552
Pediococcus pentosaceus DSM 32292
|
|
Apr 2024
Aug 2024
|
-
The FSA/FSS concluded, based on the ACAF’s advice, that the additive was correctly identified and characterised, and that the additive can be considered safe for the target species, consumer, and the environment. The additive was identified as potentially harmful by contact with skin or eyes and a respiratory sensitiser.
|
|
RP634
KemTRACE™ Chronium
Chromium Propionate
|
|
Apr 2024
Aug 2024
|
-
The FSA/FSS concluded, based on the ACAF’s advice, that the additive was correctly characterised, and that it is stable for 24 months at 25oC at 60% humidity, for 6 months as part of a premixture.
-
Homogeneity in feed was also demonstrated. The mixture was pelleted at 90oC, but retention time was not given by the applicant, therefore no conclusion could be drawn on pelleting stability. No further concerns were raised for the identity section, Section II, of the dossier.
-
No conclusion could be drawn on the prenatal developmental toxicity potential of the additive, and therefore, on the safety of the additive for consumers. The additive is non-genotoxic, and no concerns about its metabolism were raised, however, no conclusion could be drawn on the applicant’s proposed 0-hour withdrawal period, given the impossibility to conclude on the prenatal developmental toxicity potential of the additive.
-
The active substance is non-irritant to the skin, however another major ingredient, propionic acid, is corrosive to skin and eyes, and the additive should be considered as such. As the active ingredient is corrosive to skin and eyes and it may be sprayed onto the feed, it would be prudent to regard it as potentially harmful by inhalation. The additive is not a skin sensitizer.
|
|
RP812
Intellibond® C
Dicopper Chloride Trihydroxide (3b409)
|
|
Apr 2024
Jun 2024
Aug 2024
|
-
The FSA/FSS concluded, based on the ACAF’s evidence, that the additive was fully identified and characterised, and no further concerns were raised for this section of the dossier. The use of the additive at recommended levels of incorporation into feed can continue to be considered safe for the target species and the consumer.
-
Regarding user safety, the additive was determined to be non-corrosive and is not a skin sensitiser, however, is a skin irritant and should be regarded as a potential eye irritant.
|
|
RP814
Intellibond® Z
zinc chloride hydroxide monohydrate
|
|
Apr 2024
Jun 2024
Aug 2024
|
-
The Committee reviewed the application, supporting information and all RFI correspondence provided by the applicant. The RFI response was reviewed in December 2023, Members noted that in the absence of data the additive would be considered a potential eye irritant; it was also considered not to be a dermal sensitiser.
-
The FSA/FSS concluded, based on the ACAF’s advice, that the additive was correctly identified and characterised and that the changes made to the manufacturing process did not pose an unacceptable risk to safety.
|
|
RP1015
Lactococcus lactis NCIMB 30117
|
|
Apr 2024
|
|
|
RP1039/RP1040
VTR-xylanase
Containing endo-β-1,4-xylanase
|
|
Apr 2024
Jun 2024
Aug 2024
|
-
The FSA/FSS concluded, based on the ACAF’s advice, that the additive was correctly characterised, and that it is stable for 12 months in its powder form when stored at 25°C, and for 18 months in its liquid form when stored at 5°C. The additive is stable at 70°C for 15 seconds during pelleting. Homogeneity in feed was also demonstrated. No further concerns were raised for section II of the dossier.
-
The additive can be considered safe for the target species, consumers and the environment. The additive should be regarded as a skin sensitiser in both its powder and liquid form. The liquid form of the additive is not a skin irritant. In its powder form, the additive should be considered a potential skin irritant. The additive should be considered an irritant to the eyes in both forms. As an enzyme preparation, the additive should be considered a potential respiratory sensitiser.
-
VTR-xylanase is efficacious for weaned piglets, suckling piglets, minor growing porcine species, laying hens and other laying birds at 2,000 U/kg, and in chickens for fattening and minor avian species at 1,000 U/kg.
|
|
RP1111
PP102I
Bifidobacterium longum CNCM I-5642
|
|
Apr 2024
Jun 2024
Aug 2024
|
-
The FSA/FSS concluded, based on the ACAF’s advice, that the additive was correctly characterised, and that it is stable for 8 months when stored at 4°C, and in premixtures for 48 weeks at 32°C at 70% humidity, and for 88 weeks at 23°C at 60% humidity. Homogeneity in feed was also demonstrated.
-
As an organism suitable for the QPS approach to assessment, the additive can be considered safe for the consumer, the target animal, and the environment. The additive is not an irritant to the skin. The additive is an irritant to the eyes and should be considered a potential skin sensitiser and respiratory sensitiser.
|
|
RP1366
ECONASE® XT
Containing an endo‐1,4‐beta‐xylanase produced by Trichoderma reesei CBS 114044
|
|
Jun 2024
Sep 2024
Oct 2024
Dec 2024
Feb 2025
|
-
In June 2024, the Committee assessed the dossier and concluded that the additive is safe for the target species, consumers and the environment; it is not an eye or skin irritant or a skin sensitiser but should be considered a respiratory sensitiser. Members also concluded that the additive is efficacious in laying hens, minor poultry species and fattening pigs.
-
The FSA/FSS concluded, based on the ACAF’s advice, that all five forms of the additive and the production strain were correctly characterised. The liquid and solid forms of the additive are stable for 24 months at 25°C and 20-23°C, respectively. The solid forms are stable for pelleting to 95°C for 32-33 seconds and in a premixture for 6 months. All forms of the additive are stable in pelleted and mash feed for 3 months and capable of homogenous distribution in feed.
|
|
RP1400
L-lysine
|
|
Jun 2024
Sep 2024
Oct 2024
Dec 2024
|
|
|
RP1460
Miya-Gold®
(Clostridium butyricum FERM BP-2789)
(This application was withdrawn Sept 2024 but may still require an opinion)
|
|
Jun 2024
|
|
|
RP1026/RP1027
VTR-phytase
|
|
Jun 2024
Jul 2024
Sep 2024
Oct 2024
|
-
The FSA/FSS concluded, based on the ACAF’s advice, that the additive was correctly characterised. No conclusion could be reached on the stability and homogeneity of the product. No further concerns were raised for Section II of the dossier.
-
The additive can be considered safe for the target species, consumers and the environment. The active substance is non-irritant to the skin and eyes, but the additive should be regarded as skin and respiratory sensitiser. Given the high dusting potential of the powder formulation, it is advised to limit user/worker exposure through inhalation.
-
VTR-phytase has the potential to be efficacious for all avian species, sows and pigs for fattening, and is efficacious in piglets when used at the proposed dose of 500 U/kg of complete feed with 12% moisture. Conclusions can be extrapolated to all Suidae at the corresponding developmental level.
|
|
RP1070
Avatec® 150G
Lasalocid A sodium
(Renewal – Safety concern)
|
|
Jun 2024
Sep 2024
Oct 2024
Dec 2024
|
-
In January 2024, the Committee considered this request for authorisation in the context of two other related applications (RP1071 & RP1072). Due to gaps in existing documentation, additional information was requested from the applicant.
-
In October 2024, the Committee reviewed the information and documentation provided by the applicant in response to an RFI. The Committee concluded that the information provided was sufficient for assessment and that no further information would be required from the applicant. The Committee was also presented with the draft of the Committee’s Advice documents at this meeting.
|
|
RP1317
Vitamin D
25-hydroxycholecalciferol (25-OH-D3) produced by a genetically modified strain of Saccharomyces cerevisiae SC0639
|
|
Jun 2024
Oct 2024
Dec 2024
Feb 2025
|
-
In December 2023, the Committee assessed RP1317 alongside RP1350 as they share some technical documentation. Due to gaps in existing data, additional information was requested from the applicant. The applicant was asked to confirm that the production strains were the same in both applications, to confirm that they can be assessed together.
-
The FSA/FSS concluded, based on the ACAF’s advice, that the additive was correctly identified and characterised using whole genome sequencing, and upon receiving additional information, members were satisfied with the manufacturing process.
-
Upon receipt of further information relating to the inclusion rate of the additive, the ACAF concluded that the inclusion of the additive demonstrates similar effects on performance parameters when compared to vitamin D3. The Committee therefore concluded that the additive is effective in raising serum/plasma 25-OH-D3 levels in comparison with vitamin D3 for ruminants when used according to the proposed conditions of use.
|
|
RP140/ RP141/ RP142/ RP284
Coxidin®
Monensin sodium
|
-
Use in chickens for fattening, chickens reared for laying (up to 16 weeks of age), turkeys for fattening (up to 16 weeks of age) and turkeys reared for breeding (up to 16 weeks of age) as target species.
|
Jun 2024
|
-
In June 2024, results from the post-market monitoring plan for a previously evaluated application of Coxidin® (monensin sodium) were presented to the Committee for assessment. Three anticoccidial sensitivity tests were provided, with variable endpoint results.
-
The Committee concluded that, on their own, these reports did not show the existence of resistance to monensin sodium as a coccidiostat, and that based on the efficacy testing carried out as part of the application, the additive appears to remain efficacious for the control of Eimeria spp.
|
|
RP1154
BioPlus® 2B
Bacillus subtilis DSM5750 and Bacillus licheniformus DSM5749
|
-
Already authorised as zootechnical feed additive for use in feed and water for weaned piglets, pigs for fattening, sows, calves for rearing, turkeys for fattening and suckling piglets.
|
Jul 2024
Sep 2024
Oct 2024
Dec 2024
|
-
In July 2024, the Committee discussed the responses provided for various queries sent to the applicant, concluding that the questions relating to batch-to-batch variation, impurities, microbial contamination, stability and homogeneity of the final product had been correctly addressed and genetic stability had been demonstrated. The Committee requested further information from the applicant regarding materials and manufacturing.
-
The FSA/FSS concluded, based on the ACAF’s advice, that the additive was correctly characterised and both microorganisms were confirmed to be QPS. No concerns were raised for Section II of the dossier.
-
The additive can be considered safe for the target species, consumers and the environment. The active substances are presumed to be respiratory sensitisers. In the absence of data, the additive should be considered a potential skin and eye irritant, and a skin sensitiser. It is recommended that methods are adopted to minimise worker exposure to the additive.
-
BioPlus® 2B, when used at the proposed doses of 1.3 x 109 CFU/kg of complete feed (12% moisture) and 6.5 x 108 CFU/L of drinking water, has the potential to be efficacious for calves for fattening and other growing ruminants at the same developmental stage, as well as suckling piglets during the period in which solid feed is given. For suckling piglets, it is recommended to feed the additive to lactating sows simultaneously.
|
|
RP1393
RONOZYME® WX
containing endo-1,4-beta-xylanase (produced by Aspergillus oryzae DSM 33700)
|
|
Jul 2024
Dec 2024
Feb 2025
|
-
In July 2024, the Committee discussed the response provided for various queries sent to the applicant. Members were satisfied with the response however more information was requested from the applicant as Members could not conclude on the efficacy for gestating sows without additional data and therefore extrapolation to all stages of a pig’s life was not possible.
-
The FSA/FSS concluded, based on the ACAF’s advice, that the additive was fully identified and characterised. It was concluded that RONOZYME® WX (CT and L), manufactured with the A. oryzae DSM 33700 strain, did not raise any safety concerns regarding the genetic modification of the production strain. Members concluded positively on the stability and homogeneity of the additive. However, the pelleting stability for RONOZYME® WX (CT) was only tested for 20 seconds, and therefore this should be made clear on the label as some of the uses may require longer conditioning times.
-
The additive is considered safe for the target species, the consumer and the environment. The additive RONOZYME® WX (CT and L) is not a skin irritant and RONOZYME® WX (L) is not an eye irritant. RONOZYME® WX (CT) is a potential eye irritant. No information on skin sensitisation was provided; therefore, the additive is regarded as a potential skin sensitiser. The additive should be classified as a respiratory sensitiser due to the proteinaceous nature of its active ingredient (enzyme).
-
It was concluded that the additive is efficacious in all poultry species and in all pigs (Suidae) at a minimum recommended level of 100 Fungal Xylanase Units (FXU)/kg and 200 FXU/kg complete feed, respectively, with the exception to gestating sows, as no data was provided.
|
|
RP1644
Sacharromyces cerevisiae Y1242
(This application was withdrawn January 2025)
|
-
For use in dairy cows, cattle for fattening, piglets, horses, other growing ruminants and other dairy ruminants.
|
Sep 2024
|
|
|
RP1696
Bacillus velezensis ATCC PTA-6737
|
|
Sep 2024
Oct 2024
Dec 2024
Feb 2025
|
-
In December 2024, the Committee discussed the applicant’s response. Members agreed that that the reports provided were not acceptable, therefore, members will not be able to conclude on efficacy.
|
|
RP1258
Enviva® PRO 202 GT
Preparation of 3 strains of Bacillus velezensis (previously known as B. amyloliquefaciens)
|
|
Sep 2024
Oct 2024
Dec 2024
Feb 2025
|
-
The Committee concluded that the additive remains a respiratory sensitiser to the user/worker as dust can deposit in the respiratory system, therefore, the use of a respiratory mask is required when handling the additive.
-
he FSA/FSS concluded, based on the ACAF’s advice, that the additive was correctly identified and characterised, and that the additive can be considered safe for the target species, the consumer and the environment.
|
|
RP1649
Patent Blue V
(sodium salt of 2-[(4-diethylaminophenyl)(4-diethylimino-2,5-cyclohexadien-1-ylidene)methyl]-4-hydroxy-1,5-benzene-disulfonate)
(Renewal – Safety concerns)
|
|
Oct 2024
|
|
|
RP1888
Lactiferm®
Enterococcus faecium NCIMB 11181
(This application was withdrawn January 2025)
|
|
Oct 2024
Dec 2024
|
-
In October 2024, the Committee reviewed this dossier and carried out an assessment on the efficacy section.
-
Members stated that three out of the six trials show a positive effect for efficacy, however, the remaining three studies showed little potential for efficacy.
-
It was concluded that not enough evidence for efficacy has been provided in chickens for fattening to be able to extrapolate to all growing poultry and ornamental birds.
-
A request for further information to support the efficacy of the additive was sent to the applicant.
-
In December 2024 Members discussed the applicant’s response and reviewed the information and documentation provided, the Committee determined that evidence provided was insufficient and therefore could not conclude on efficacy.
|
|
RP2074
FUMzyme®
(fumonisin esterase EC 3.1.1.87) from Komagataella phaffii (DSM 32159)
|
|
Oct 2024
|
-
In October 2024, the Committee reviewed the dossier and noted that the applicant needed to provide clarity in certain areas and requested the applicant supply further information regarding the identity and characterisation of the additive.
-
Members could not conclude on eye irritancy using the test provided. No studies for skin sensitisation were provided, therefore the additive should be considered a potential skin sensitiser. The additive is also an enzyme product, therefore should be regarded as a potential respiratory sensitiser. Members confirmed that this additive would be classed as non-irritant to the skin.
-
The Committee could not conclude on efficacy highlighting some concerns around the dairy cattle and fish studies.
-
A request for further information to support the additive seeking authorisation was sent to the applicant.
|
|
RP1055/RP1582
Huvezym® neXo
Peparation of endo 1,4 betaxylanase, endo 1,4
betaglucanase and xyloglucan-specific-endo-beta-1,4-glucanase)
(RP1055 was withdrawn December 2024)
|
-
Proposed for use in poultry, ornamental birds and piglets (RP1055) and pigs for fattening, sows, minor species for fattening and reproduction (RP1582).
|
Oct 2024
|
-
The Committee were able to conclude that the additive is efficacious in weaned and suckling piglets, and sows. Further clarification was provided for chickens for fattening, allowing members to conclude positively on efficacy for chickens for fattening.
|
|
RP1904
Biomin® C5
Enterococcus faecium (DSM 33761), Pediococcus acidilactici (DSM 33758), Bifidobacterium animalis (DSM 16284), Limosilactobacillus reuteri (DSM 33751) and Ligilactobacillus salivarius (DSM16351)
|
|
Dec 2024
|
-
Supplementary data provided by the applicant was reviewed by the Committee offline and Members concluded that the additive has the potential to be efficacious for chickens for fattening under the proposed conditions of use. This conclusion can be extrapolated to chickens reared for laying, turkeys for fattening and reared for breeding and minor avian species other than laying species based on the data provided.
|
|
RP2071
Enterosure™ Conc
Bacillus velezensis (ATCC PTA-6737) and ATCC PTA-127114), Bacillus licheniformis (ATCC-127113)
|
|
Dec 2024
|
-
The application referred to Enterosure™ Conc, but also to a less concentrated form in a calcium carbonate carrier, termed Enterosure™; the Committee agreed that for the purposes of the discussion, both forms would be considered.
|
|
RP2107
Availa® Cr
Chromium chelate of DL-methionine
|
|
Dec 2024
|
|
|
RP1275
Quantum® Blue
6-phytase (EC 3.1.3.26) produced by Trichoderma reesei
|
|
Dec 2024
Feb 2025
|
-
Additional information was requested from the applicant, and this was reviewed in January. There were still gaps in the existing documentation, so a further request for information was sent to the applicant.
|
|
RP1592
Interban®
10 % Narasin and 0.2 % Diclazuril
|
|
Feb 2025
|
-
The Committee concluded that the additive is a potential irritant to the eyes and skin, and appropriate measures should be taken to avoid contact. The additive is also a skin and respiratory sensitiser, and measures should be taken to ensure contact with skin and inhalation is avoided. No concerns were raised by the Committee regarding the additive’s safety for the environment. Members also concluded that the additive is not genotoxic.
|
|
RP2156
Copper lysinate sulfate
(This application was withdrawn January 2025)
|
|
Feb 2025
|
|
|
RP2157
Bovacillus 10 ® and Bovacillus® WS
(Bacillus paralicheniformis DSM 33902 + Bacillus subtilis DSM 33903)
|
|
Feb 2025
|
|
|
RP1499
Balancius® Muramidase (solid and liquid forms)
(ABB Assessment)
|
|
Dec 2024
|
|